June 2015—Thermo Fisher Scientific announced the release of the CE-IVD Oncomine Solid Tumour Fusion Transcript kit designed to aid clinical decision-making and enable highly accurate and reliable multiplexed sequencing of formalin-fixed, paraffin-embedded tumor samples.
Marked for in vitro diagnostic use in the European Union, the kit, for next-generation sequencing, enables the detection of rearrangements involving the ALK, ROS-1, RET, and NTRK1 genes from as little as 10 ng of RNA. The target content, focusing on lung cancer but potentially applicable to other solid tumors, was verified with leading clinical researchers from the OncoNetwork Consortium, which comprises 12 translational cancer research institutes spanning 10 different countries and has years of experience in implementing NGS technologies in clinical laboratories.
Thermo Fisher Scientific, 760-603-7200